PriceTargets.com logo

Galera Therapeutics - GRTX Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.12 As of 07/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for GRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Galera Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.12.

This chart shows the closing price for GRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 4 polled investment analysts is to reduce stock in Galera Therapeutics. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2023HC WainwrightDowngradeBuy ➝ NeutralLow
8/14/2023CitigroupDowngradeBuy ➝ NeutralLow
8/11/2023Bank of AmericaDowngradeUnderperformLow
8/10/2023Piper SandlerDowngradeOverweight ➝ NeutralN/A
3/22/2023HC WainwrightLower TargetBuy$10.00 ➝ $6.00Low
3/16/2023CitigroupLower Target$18.00 ➝ $12.00Low
2/21/2023Piper SandlerInitiated CoverageOverweight$6.00Low
2/16/2023HC WainwrightReiterated RatingBuy$10.00Low
2/16/2023Bank of AmericaUpgradeUnderperform ➝ Buy$2.00 ➝ $7.00Low
11/28/2022CitigroupLower Target$20.00 ➝ $18.00Low
6/30/2022HC WainwrightReiterated RatingBuy$10.00Low
5/27/2022Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
12/20/2021CitigroupBoost TargetBuy$11.00 ➝ $20.00High
12/15/2021HC WainwrightUpgradeNeutral ➝ Buy$10.00High
12/14/2021BTIG ResearchUpgradeNeutral ➝ Buy$15.00High
12/14/2021Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
10/21/2021CitigroupLower TargetBuy$21.00 ➝ $11.00Medium
10/20/2021HC WainwrightDowngradeBuy ➝ NeutralMedium
10/19/2021Bank of AmericaDowngradeBuy ➝ Underperform$17.00 ➝ $2.00N/A
10/19/2021BTIG ResearchDowngradeBuy ➝ NeutralN/A
9/26/2021BTIG ResearchReiterated RatingBuy$30.00High
9/24/2021HC WainwrightReiterated RatingBuy$15.00High
9/9/2021HC WainwrightReiterated RatingBuy$15.00Low
6/29/2021HC WainwrightReiterated RatingBuy$15.00Medium
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$15.00High
12/16/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$9.00 ➝ $15.00Medium
12/7/2020HC WainwrightInitiated CoverageBuy$15.00High
11/11/2020Credit Suisse GroupBoost TargetNeutral$8.00 ➝ $9.00Low
10/28/2020Smith Barney CitigroupBoost Target$18.00 ➝ $21.00High
7/29/2020Credit Suisse GroupLower TargetNeutral$14.00 ➝ $8.00Low
12/2/2019BTIG ResearchInitiated CoverageBuy$30.00High
12/2/2019Credit Suisse GroupInitiated CoverageNeutral$14.00High
12/2/2019CitigroupInitiated CoverageBuy$20.00High
12/2/2019Bank of AmericaInitiated CoverageBuy$15.00High
(Data available from 7/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Galera Therapeutics logo
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.12
Low: $0.12
High: $0.13

50 Day Range

MA: $0.14
Low: $0.08
High: $0.23

52 Week Range

Now: $0.12
Low: $0.07
High: $2.74

Volume

27,454 shs

Average Volume

1,690,309 shs

Market Capitalization

$6.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Galera Therapeutics?

The following Wall Street research analysts have issued reports on Galera Therapeutics in the last year: Bank of America Co., Citigroup Inc., HC Wainwright, and Piper Sandler.
View the latest analyst ratings for GRTX.

What is the current price target for Galera Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Galera Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Galera Therapeutics in the next year.
View the latest price targets for GRTX.

What is the current consensus analyst rating for Galera Therapeutics?

Galera Therapeutics currently has 1 sell rating and 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for GRTX.

What other companies compete with Galera Therapeutics?

Other companies that are similar to Galera Therapeutics include Lannett, Enlivex Therapeutics, Akari Therapeutics, Bolt Biotherapeutics and Clene. Learn More about companies similar to Galera Therapeutics.

How do I contact Galera Therapeutics' investor relations team?

Galera Therapeutics' physical mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The company's listed phone number is 610-725-1500 and its investor relations email address is [email protected]. The official website for Galera Therapeutics is www.galeratx.com. Learn More about contacing Galera Therapeutics investor relations.